Floatz logo

SODIUM ZIRCONIUM CYCLOSILICATE

Hypertension

Brigham and Women's HospitalSmall moleculePhase 4 / ApprovedDormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Hypertension cohort.

Asset / SponsorPhaseRating
VALSARTAN
University of Alabama at Birmingham
Phase 4BBB
Hydrochlorothiazide
University of Kansas Medical Center
Phase 4BBB
AMLODIPINE
Jing Liu
Phase 4BBB
Losartan
Rong Zhang
Phase 4BBB
Trandolapril
University of Florida
Phase 4BBB

View all 50 →

Same molecule, other indications

SODIUM ZIRCONIUM CYCLOSILICATE is also rated in:

Metabolic SyndromeDormant
B
Indicative ·
57 / 100
View asset →
Duchenne Muscular DystrophyDormant
CCC
Indicative ·
51 / 100
View asset →
Endothelial DysfunctionDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →